Market revenue in 2023 | USD 480.1 million |
Market revenue in 2030 | USD 647.0 million |
Growth rate | 4.4% (CAGR from 2023 to 2030) |
Largest segment | Drug delivery |
Fastest growing segment | Therapeutics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Drug Delivery, Therapeutics, In-vitro Diagnostics, Implants, In-vivo Imaging |
Key market players worldwide | Abbott Laboratories, Invitae Corp, Celgene, GE HealthCare Technologies Inc Common Stock, Johnson & Johnson, Mallinckrodt PLC Ordinary Shares - New, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Arrowhead Pharmaceuticals Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nanomedicine market will help companies and investors design strategic landscapes.
Drug delivery was the largest segment with a revenue share of 34.24% in 2023. Horizon Databook has segmented the Kuwait nanomedicine market based on drug delivery, therapeutics, in-vitro diagnostics, implants, in-vivo imaging covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Kuwait nanomedicine market , including forecasts for subscribers. This country databook contains high-level insights into Kuwait nanomedicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account